

03.12.2019

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building,
Phirozejeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services,
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.
Scrip Code : CAPLIPOINT

By NEAPS

Dear Sirs,

SUB:PRESS RELEASE- DISCLOSURE UNDER REGULATION 30 OF SEBI(LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015.

Please find the enclosed copy of Press Release being published today.

Thanking you,

Yours Faithfully,
For **CAPLIN POINT LABORATORIES LIMITED**


COMPANY SECRETARY
Enclosure: As above



PRESS RELEASE

CAPLIN STERILES GETS USFDA APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION

Chennai, Dec 3, 2019: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited, a Wholly Owned Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sodium Nitroprusside injection, 50 mg/2 mL (25 mg/mL) Vial, a generic therapeutic equivalent version of NITROPRESS (Sodium Nitroprusside) 50 mg/vial of Hospira Worldwide, INC . According to IQVIA™ (IMS Health), Sodium Nitroprusside had US sales data of approximately \$8 million for the 12-months period ending March 2019. Caplin Steriles Limited, has developed and filed 13 ANDAs on its own and with partners, with 6 approvals so far.

Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure.

Mr.C.C.Paarthipan, Chairman of Caplin Point Laboratories Limited commented “This is the third ANDA approval under Caplin Steriles name and we hope to have a couple more in the next few months, which should help us close the year strongly. Added to this, our entry into captive API manufacturing for several of our ANDAs should augment our control over Compliance, Cost and Continuity in supply.” The Company is also working on a portfolio of 35 simple and complex Injectable and Ophthalmic products, to be filed over the next 4 years.

ABOUT CAPLIN POINT LABORATORIES LIMITED:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical Company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company's Wholly Owned Subsidiary Caplin Steriles Limited caters to the Regulated Markets for Injectable and Ophthalmic products.

Caplin Point Laboratories Limited has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.





Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations Team at Caplin

Mr. Vinod Kumar (Company Secretary)

Tel: +91 44 24968000

investor@caplinpoint.net

Dikshita Jain

Christensen Investor Relations

Tel : +91 22 4215 0210

djain@christensenir.com

Registered Office

Narbhavi No. 3, Lakshmanan Street,
T Nagar, Chennai, Tamil Nadu, 600017

Telephone: 044-28156653

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: www.caplinpoint.net

